Jenny Seligmann, Professor of Gastrointestinal Oncology at the University of Leeds, shared a post by Myriam Chalabi on X, adding:
”Neoadjuvant IO for locally advanced MSS colon ca…. This article helps us take a further step forward by demonstrating clear efficacy and signals towards biomarkers for pt selection.
Huge congrats to my team neoadjuvant dear friend and team! We will get there in colon cancer.”
Quoting Myriam Chalabi‘s post:
”Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in Nature after presentation on ESMO. Preview.
Read on how genomic instability, P53mt and proliferation may aid in predicting responses.
What changes do we see in the TME post IO? Does it differ between responders and nonresponders?Tumor reactive phenotypes, and not quantity, of T cells enriched in responders as observed in bulk RNAseq, imaging mass cytometry and single cell RNAseq.
Stay tuned for a detailed tweet. First, rounding up the last day of ESMO25.”
Title: Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
Authors: Pedro B. Tan, Yara L. Verschoor, José G. van den Berg, Sara Balduzzi, Niels F. M. Kok, Marieke E. Ijsselsteijn, Kat Moore, Adham Jurdi, Antony Tin, Paulien Kaptein, Monique E. van Leerdam, John B. A. G. Haanen, Emile E. Voest, Noel F. C. C. de Miranda, Ton N. Schumacher, Lodewyk F. A. Wessels, Myriam Chalabi
You can read the Full Article.
More posts featuring Jenny Seligmann on OncoDaily.